Skip to main content

Advertisement

Table 3 Key baseline laboratory data (treated set; n = 7034)

From: Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™)

HbA1c (%), mean (SD) 8.1 (0.8)
HbA1c <8.5%, n (%) 4811 (68)
Fasting plasma glucose (mmol/L), mean (SD) 8.5 (2.4)
Body mass index (kg/m2), mean (SD) 30.6 (5.3)
≥ 35 kg/m2, n (%) 1426 (20)
Weight (kg), mean (SD) 86.4 (18.9)
Waist circumference (cm), mean (SD) 105 (14)
Systolic/diastolic blood pressure (mmHg), mean (SD) 135 (17)/77 (10)
Lipids (mmol/L), mean (SD)  
  Total cholesterol 4.2 (1.1)
  LDL-cholesterol 2.2 (0.9)
  HDL-cholesterol 1.2 (0.3)
  Triglycerides 1.9 (1.4)
eGFR according to MDRD (mL/min/1.73 m2), mean (SD) 74 (21)
eGFR according to MDRD (mL/min/1.73 m2), n (%)  
  ≥90 1534 (22)
  60 to <90 3671 (52)
  30 to <60 1796 (26)
ACR albumin ratio (mg/g), median (Q1, Q3) 17.7 (7.1, 72.5)
ACR ratio (mg/g), n (%)  
  ≥ 30 – 300 2011 (29)
  ≥ 300 771 (11)
  1. Results (based on a pre-final version of the database of this ongoing trial) may change slightly once trial is completed.